Modality
Degrader
MOA
STINGag
Target
GPRC5D
Pathway
Autophagy
CRCNarcolepsy
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
Jun 2017
→ Feb 2031
Phase 3Current
NCT03999520
1,655 pts·Narcolepsy
2017-12→2028-09·Not yet recruiting
NCT07677089
295 pts·CRC
2017-06→2031-02·Completed
NCT06769903
351 pts·CRC
2025-08→2029-02·Not yet recruiting
2,301 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2028-09-222.5y awayPh3 Readout· Narcolepsy
2029-02-112.9y awayPh3 Readout· CRC
2031-02-094.9y awayPh3 Readout· CRC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Complet…
P3
Not yet…
P3
Not yet…
Catalysts
Ph3 Readout
2028-09-22 · 2.5y away
Narcolepsy
Ph3 Readout
2029-02-11 · 2.9y away
CRC
Ph3 Readout
2031-02-09 · 4.9y away
CRC
CompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03999520 | Phase 3 | Narcolepsy | Not yet recr... | 1655 | BodyWt |
| NCT07677089 | Phase 3 | CRC | Completed | 295 | UPCR |
| NCT06769903 | Phase 3 | CRC | Not yet recr... | 351 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |